The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study
暂无分享,去创建一个
Douglas G Altman | Peter Jüni | Eveline Nüesch | Sven Trelle | Martin Scherer | Anne W S Rutjes | D. Altman | A. Rutjes | P. Jüni | S. Reichenbach | M. Scherer | S. Trelle | Stephan Reichenbach | Elizabeth Bürgi | E. Nüesch | E. Bürgi | E. Nüesch | P. Jüni
[1] David Moher,et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials , 2001, Annals of Internal Medicine.
[2] D. Moher,et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Journal of the American Podiatric Medical Association.
[3] Douglas G Altman,et al. Statistical methods for assessing the influence of study characteristics on treatment effects in ‘meta‐epidemiological’ research , 2002, Statistics in medicine.
[4] D. Sackett,et al. Controversy in counting and attributing events in clinical trials. , 1979, The New England journal of medicine.
[5] Lesley A Stewart,et al. Investigating patient exclusion bias in meta-analysis. , 2004, International journal of epidemiology.
[6] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[7] B. Beermann,et al. Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications , 2003, BMJ : British Medical Journal.
[8] S. Julious,et al. Issues with using baseline in last observation carried forward analysis , 2008, Pharmaceutical statistics.
[9] G. Guyatt,et al. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis , 2002, BMJ : British Medical Journal.
[10] Anna C. Balazs,et al. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. , 1980, The New England journal of medicine.
[11] M. Egger,et al. Commentary: Empirical evidence of attrition bias in clinical trials. , 2004, International journal of epidemiology.
[12] David L Streiner,et al. The Case of the Missing Data: Methods of Dealing with Dropouts and other Research Vagaries , 2002, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[13] Mimi Y. Kim. Statistical methods in Arthritis & Rheumatism: current trends. , 2006, Arthritis and rheumatism.
[14] S. Reichenbach,et al. Meta-analysis: Chondroitin for Osteoarthritis of the Knee or Hip , 2007, Annals of Internal Medicine.
[15] A. Astrup,et al. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis , 2006, Annals of the rheumatic diseases.
[16] A. Klovning,et al. Short‐term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta‐analysis of randomised placebo‐controlled trials , 2007, European journal of pain.
[17] S. Hollis,et al. What is meant by intention to treat analysis? Survey of published randomised controlled trials , 1999, BMJ.
[18] Sally Morton,et al. Meta-Analysis: Chronic Disease Self-Management Programs for Older Adults , 2005, Annals of Internal Medicine.
[19] S. Mcconnell,et al. Exercise for osteoarthritis of the hip or knee. , 2001, The Cochrane database of systematic reviews.
[20] D. Spiegelhalter,et al. Disease Mapping With WinBUGS and MLwiN, Bayesian Approaches to Clinical Trials and Health Care Evaluation , 2004 .
[21] B. Leeb,et al. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. , 2006, Archives of internal medicine.
[22] M. Hochberg,et al. Acetaminophen for osteoarthritis. , 2006, The Cochrane database of systematic reviews.
[23] J. Hilden,et al. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. , 2007, International journal of epidemiology.
[24] R. J. Hayes,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.
[25] Ross J. Harris,et al. Correction: reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. , 2008, Annals of internal medicine.
[26] Christian Gluud,et al. Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses , 2001, Annals of Internal Medicine.
[27] V. Welch,et al. Glucosamine therapy for treating osteoarthritis. , 2005, The Cochrane database of systematic reviews.
[28] R. Haynes,et al. Optimal search strategies for retrieving systematic reviews from Medline: analytical survey , 2004, BMJ : British Medical Journal.
[29] D. Moher,et al. The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.
[30] Mark I. Johnson,et al. Short-term efficacy of physical interventions in osteoarthritic knee pain. A systematic review and meta-analysis of randomised placebo-controlled trials , 2007, BMC musculoskeletal disorders.
[31] S. Shapiro,et al. The intention-to-treat approach in randomized controlled trials: Are authors saying what they do and doing what they say? , 2007, Clinical trials.
[32] M. Dougados,et al. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. , 2007, Osteoarthritis and cartilage.
[33] Ethan M Balk,et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. , 2002, JAMA.
[34] D. Felson,et al. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. , 2003, JAMA.
[35] A. Samson,et al. Missing data in randomized controlled trials of rheumatoid arthritis with radiographic outcomes: a simulation study. , 2008, Arthritis and rheumatism.
[36] Peter Jüni,et al. Quality of reporting of randomized trials as a measure of methodologic quality. , 2002, JAMA.
[37] Klaus Linde,et al. Meta-analysis: Acupuncture for Osteoarthritis of the Knee , 2007, Annals of Internal Medicine.
[38] S. Reichenbach,et al. Osteoarthritis: rational approach to treating the individual. , 2006, Best practice & research. Clinical rheumatology.
[39] I. Boutron,et al. Violation of the intent-to-treat principle and rate of missing data in superiority trials assessing structural outcomes in rheumatic diseases. , 2005, Arthritis and rheumatism.
[40] B. Djulbegovic,et al. Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group , 2004, BMJ : British Medical Journal.
[41] M Alan Brookhart,et al. Meta-analyses involving cross-over trials: methodological issues. , 2011, International journal of epidemiology.
[42] M Egger,et al. Value of flow diagrams in reports of randomized controlled trials. , 2001, JAMA.
[43] Douglas G Altman,et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study , 2008, BMJ : British Medical Journal.